TNGX — Tango Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1819133 ·
Last close
$22.11
Market Cap
$3.75B
52W High
$34.39
52W Low
$7.69
ADV30
4,052,487
Next earnings
2026-11-09
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -78,116,000 -68,394,000 1,033,460,000 86,835,000 53,287,000
Jun 2026 0 — -59,785,000 -55,341,000 1,073,880,000 345,558,000 49,348,000
Mar 2026 0 — -48,769,000 -45,514,000 435,792,000 157,828,000 44,286,000
Dec 2025 0 — -41,864,000 -38,749,000 398,690,000 112,279,000 52,511,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-150,087,000
Investing CF
$-796,037,000
Financing CF
$974,193,000
CapEx
$-1,048,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.37
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-772,401,000
Inventory
—
Receivables
—
ST Investments
$890,668,000
EBIT TTM
$-228,534,000
Pretax Income TTM
$-208,051,000
Interest Exp TTM
—
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-226,748,000
Free Cash Flow
$-80,177,376
Enterprise Value
$3,374,782,464
Total Cash
$977,502,976
Total Debt
$31,179,000
Shares Out
169,455,160
Trailing EPS
$-1.38
Book Value
$5.79
ROE
-36.5%
ROA
-23.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 62,384,000 -111,289,000 -101,594,000 398,690,000 52,511,000 346,179,000 -138,886,000
Dec 2024 42,069,000 -145,595,000 -130,302,000 316,492,000 116,975,000 199,517,000 -131,501,000
Dec 2023 36,527,000 -114,173,000 -101,744,000 402,567,000 149,459,000 253,108,000 -117,982,000
Dec 2022 24,860,000 -111,071,000 -108,176,000 436,470,000 186,994,000 249,476,000 -109,080,000

TTM Snapshot

Revenues TTM
$53,811,000
NetIncome TTM
$-123,720,000
OpCashFlow TTM
—
Assets (Latest)
$1,073,880,000
Forward EPS
$-1.80

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $27.00 · spot: $21.89 · call volume: 1,879 · put volume: 3,725

Peers — same industry

TickerNameMarket CapLastDaily %
XENE Xenon Pharmaceuticals Inc. $3.81B $38.78 —
OGN Organon & Co. $3.65B $13.90 —
ABCL AbCellera Biologics Inc. $3.60B $11.03 —
SLS SELLAS Life Sciences Group, Inc. $3.90B $19.15 —
AMLX Amylyx Pharmaceuticals, Inc. $3.54B $27.52 —

News headlines (Yahoo Finance, 1h cache)

A $52 Billion Fund Bought These 3 Stocks
2026-11-14 11:56 · Yahoo
Tango Therapeutics Stock Has The Bull Case Changed After JPMorgan Backing
2026-11-12 06:09 · Yahoo
Erasca Stock In Focus As Combination Trial Begins
2026-11-12 03:13 · Yahoo
JPMorgan highlights stock on Analyst Focus List after 3Q results
2026-11-11 17:15 · Yahoo
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
2026-11-09 12:00 · Yahoo
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
2026-11-04 13:30 · Yahoo
Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
2026-11-03 12:00 · Yahoo
Tango Therapeutics (TNGX) Following Trial Update Has Its Valuation Story Back In Focus
2026-10-28 17:11 · Yahoo
Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?
2026-10-28 13:16 · Yahoo
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
2026-10-23 20:06 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.